Clinical relevance of extracellular vesicles RNAs as non-invasive prognostic biomarkers in prostate cancer.
Extracellular vesicles (EVs), such as exosomes, microvesicles, or oncosomes, are secreted membrane-enclosed vesicles produced by all types of cells. EVs carry distinct repertoires of proteins, lipids, metabolites and nucleic acids (DNA and RNA), and their cargo is controlled by specific molecular sorting machineries. EVs coming from tumor cells can circulate in fluids like plasma and urine and can vehicle biomarkers protected from potential degradation by nucleases, proteases or other environmental stressors. Consequently, EVs can be an excellent material to help for a better understanding of cancer biology and to discover novel biomarkers for cancer diagnostics and prognosis and for therapeutic options.
To define novel RNA biomarkers for prostate cancer prognostic, we analyze the full transcriptome of urinary and blood extracellular vesicles from healthy and prostate cancer (PCa) patients and compare it with prostate tumor tissues transcriptome. Finally, we orientate future functional studies of selected PCa-EVs biomarkers using prostate cell lines that produce EVs carrying these biomarkers.
Current projects:
- Comparison of urinary EVs and tumor cells RNA cargoes from prostate cancer patients.
- Clinical relevance of urine and blood derived extracellular vesicles (EVs) to define RNA biomarkers for non-invasive prognosis of prostate cancer.
- Functional study of selected urinary and blood EVs biomarkers from prostate cancer patients.
Our collaborators :
# Clotilde Théry (institut Curie, France)
# Francis Vacherot, Virginie Firlej et Damien Destouches (TRePCa - Résistances Thérapeutiques du Cancer de la Prostate, UPEC – UFR de Santé, Créteil, FRance)
# Daniel Gautheret (I2BC, Gif sur Yvette, France)
# Prof Alexandre de la taille (Mondor hospital, Creteil, France)
# Prof Yves Allory (Head of Pathology, Institut Curie, St-Cloud & Hôpital Foch, Suresnes, France)